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doi:10.1016/j.ejvs.2010.06.018Abstract Aims: The efficacy of endovenous treatments for venous reflux has been demon-
strated in numerous randomised clinical trials, although significant heterogeneity may exist
between studies. The aim of this study was to assess the heterogeneity in reporting between ran-
domised clinical trials investigating endovenous treatments for patients with varicose veins.
Methods: A literature search of the Pubmed, Cochrane and Google Scholar databases was per-
formed using appropriate search terms. Randomised clinical trials published between January
1968 and June 2009 evaluating endovenous interventions for varicose veins were included and
relevant abstracts and full text articles were reviewed. Published study reports were evaluated
against recommended reporting standards published by the American Venous Forum in 2007.
Results: Twenty-eight randomised trials fulfilled the inclusion criteria. Median patient age (re-
ported in 20/28 studies) ranged from 33 to 54 years. The CEAP classification was presented in
17/28 studies and the proportion of patients with C2 disease ranged from 6.3% to 83.5%. A total
of 31 different outcome measures were utilised. This included 13 different questionnaires, vari-
cose vein recurrence at 38 time points and 30 categories of complications. Duplex ultrasonog-
raphy was used in 21/28 trials to assess recurrence. Quality of life was only evaluated in 11
studies and the follow-up period ranged from 3 weeks to 10 years.
Conclusions: Meaningful comparison across randomised studies of endovenous treatments is
made difficult by considerable variations in study populations and outcome measures between
trials. This highlights the need for the use of prospectively agreed population selection, and re-
porting standards for outcome measures in randomised clinical assessments of new treatments.
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Heterogeneity of Reporting Standards in Randomised Clinical Trials 529Introduction foam”, “cryosurgery”, “sclerotherapy”, “endovenousVaricose veins and associated complications are extremely
common, with a UK adult prevalence of 25e33%.1,2
Patients may be asymptomatic, although pain, swelling,
eczema, skin pigmentation, and eventual ulceration are
common symptoms.1 For all severities of disease, treat-
ment of superficial venous reflux has been shown to
improve quality of life (QOL) in patients with varicose
veins.3
A variety of surgical and endovenous modalities are
currently available for the treatment of superficial venous
reflux. Traditional surgery involves ligation and stripping of
the refluxing great (GSV) or small saphenous veins (SSV) and
ambulatory phlebectomy, although endovenous technolo-
gies to ablate refluxing veins have become popular. Tech-
niques include ultrasound guided foam sclerotherapy
(UGFS), radiofrequency ablation (RFA) and endovenous
laser ablation (EVLA). These interventions have been
evaluated in numerous randomised clinical studies,
although the heterogeneity of study populations and
outcomes assessed is unknown.
Reporting standards in venous disease were published
originally by the American Venous Forum in 1988,4 and
further modified in 19955and 2004;6 the 2004 publication
separated CEAP C4 into C4a and C4b. A further guide was
published for reporting standards in endovenous ablation
for venous insufficiency in 2007.7 The purpose of these
standards was to encourage uniformity in the reporting
of trials assessing treatment modalities for venous
disease. The aim of this study was to assess the
heterogeneity in reporting between randomised clinical
trials investigating endovenous treatments for patients
with varicose veins.
Methods
A literature search of the Pubmed, Cochrane and Google
Scholar databases was performed, using the search terms
“varicose veins”, “ligation”, “saphenous vein”, “sclerosantArticles 
sear
(n
Potential randomised tria
(n = 124) 
Randomised trials matching 
inclusion criteria 
(n = 28)
Not m
Figure 1 Summary of the reslaser” and “radiofrequency ablation” within ‘All fields’ with
appropriate search limits. All abstracts were reviewed and
relevant full text articles were obtained. Reference lists
and ‘related articles’ were also scrutinised to identify all
relevant publications. Only randomised trials evaluating
endovenous interventions for varicose veins published
between January 1968 and June 2009 were included. Non-
randomised trials were not included. Other exclusion
criteria were:
 Trials where no patient group received an endovenous
treatment,e.g. comparing twodifferent surgicalmethods
 All groups within the trial received different forms of the
same endovenous treatment, e.g. different sclerosants
 Studies of treatments for venous ulceration
From each study, details of patient demographics,
anatomical information, follow-up period and outcome
measures were recorded. Study details were compared to
the “recommended reporting standards” published by the
American Venous Forum in 2007.7Results
Results of literature search
A total of 2384 results were obtained from the search
criteria, of which 28 randomised trials fulfilled the inclusion
criteria (Fig. 1). All studies were published between 1968
and 2009. Details of the included studies are presented in
Table 1.
Study populations, demographics and baseline
clinical characteristics
Patient age was recorded in 20 of the 28 studies (median
age range 33e54 years between studies) and gender was
reported in 23 of 28. Other important characteristics foridentified from 
ch strategy 
= 2384) 
ls  Duplicates and irrelevant  
articles from abstract 
(n = 2260)
atching inclusion criteria 
(n = 96) 
ults of the search strategy.
Table 1 The details of patient demographics, anatomical information, methods and outcome measures recorded from each ncluded study. The recommended details from
the 2007 American Venous Forum reporting standards are shown in italics.7 Outcome measures were recorded at numerous fferent follow-up time points.
Author Year Treatment
Modality 1
Treatment
Modality 2
Time Points for
Follow-up
Age
Recorded
Sex
Recorded
QOL
Assessed
Post-2007
Disselhoff13 2009 Cryostripping Endovenous Laser Ablation 6 weeks, 6/12/24 months Yes Yes Yes
Almeida14 2009 RadioFrequency
Ablation
Endovenous Laser Ablation 24e72 h, 1/2 weeks, 1 month, Yes Yes Yes
Darwood15 2008 Surgery Endovenous Laser Ablation 1/6/12 weeks and 1 year Yes Yes Yes
Disselhoff16 2008 Cryostripping Endovenous Laser Ablation  SFJ
Ligation
6/12/24 months Yes No No
Abela17 2008 Surgery Sclerotherapy 2 weeks Yes Yes No
Kalteis18 2008 Surgery Endovenous Laser Ablation 2 days, 1/4/16 weeks Yes Yes Yes
Rasmussen19 2007 Surgery Endovenous Laser Ablation 12 days, 1/3/6 months,
1/2/3/4/5 years
Yes Yes Yes
Lin20 2007 Surgery Endovenous Laser Ablation 1/6/12 months Yes Yes No
Lorenz21 2007 Surgery Bipolar Coagulating Electric
Vein
Stripper
24 h, 1/3/4 weeks Yes Yes Yes
Pre-2007
Michaels22 2006 Surgery Sclerotherapy 1/6 months and 1 year Yes Yes Yes
Bountouroglou23 2006 Surgery Sclerotherapy 3 weeks, 3 months Yes Yes Yes
Hinchliffe24 2006 Surgery Radiofrequency Obliteration First 10 days, 6 weeks, 1 year Yes Yes No
Arenas-Ricart25 2006 Surgery 3-S Saphenectomy 12 months No Yes No
De Medeiros26 2005 Surgery Endovenous Laser Ablation Day 7/13/16, 2e18 months (mea ) Yes Yes No
Lurie27 2005 Surgery Radiofrequency Obliteration 72 h, 1/3 weeks, 4 months, 1/2 y rs No No Yes
Perala28 2005 Surgery Radiofrequency Obliteration 8 weeks, 3 years Yes Yes No
Khale29 2004 Sclerotherapy Placebo 1/4/12 weeks Yes Yes No
Lurie30 2003 Surgery Radiofrequency Obliteration 72 h, 1/3 weeks, 4 months Yes Yes Yes
Belcaro31 2003 Surgery Sclerotherapy 5 years, 10 years Yes Yes No
De Roos32 2003 Surgery Sclerotherapy 5/14 days, 2/4 weeks, 1/2 years Yes Yes No
Rautio33 2002 Surgery Radiofrequency Obliteration Through 1st week, 2/4/8 weeks Yes Yes Yes
Belcaro34 2000 Surgery Sclerotherapy 10 days, 1/3/6 months,
2/4/6/8/10 years
Yes Yes No
Rutgers35 1994 Surgery Sclerotherapy 3 months, 1/2/3 years No Yes No
Jakobsen36 1979 Surgery Sclerotherapy 3 months, 3 years No Yes No
Beresford37 1978 Surgery Sclerotherapy 1/2/3/4/5 years No No No
Hobbs38 1974 Surgery Sclerotherapy 6 monthly for 6 years No No No
Chant39 1972 Surgery Sclerotherapy 6 months, 1/2/3 years No No No
Hobbs40 1968 Surgery Sclerotherapy 12 month average No No No
QOL, quality of life; SFJ, sapheno-femoral junction.
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Heterogeneity of Reporting Standards in Randomised Clinical Trials 531comparison between the patients in various studies such as
co-morbidities and body mass index (BMI) were poorly
reported. The CEAP classification was presented in 17 of
the 28 studies, although only nine of these provided the
exact distribution of patients in to CEAP groups 1e6.
Outcome measures assessed
Within the studies included, numerous measures of
treatment efficacy were assessed. Thirty categories of
complications were recorded with infection, phlebitis,
pain, haematoma and paraesthesia being the most
common (Table 2). The follow-up periods between studies
ranged from 3 weeks to 10 years. Recurrence of varicose
veins was assessed at 38 different time points ranging from
one day to 10 years. Twenty-five studies measured recur-
rence as an end-point of treatment, and of these, 21 used
venous duplex ultrasonography as an objective assessment
of recurrence. Three studies measured ambulatory venous
pressure or refill time in addition to Duplex. Five of the
seven studies that did not use duplex as a part of their
assessment of recurrence were all pre-1980, at which time
duplex scanning was not routinely available. The remain-
ing two studies were not assessing recurrence as an end-
point.
Thirteen different validated questionnaires were used
and several additional non-validated questionnaires were
also employed. Validated QOL assessments were not avail-
able until 1993 (when Short Form-36 was introduced).8,9 Of
the 23 trials were published post-1993, only 11 assessed
QOL with a validated questionnaire.Table 2 Included randomised controlled trials in varicose vein in
basic demographic details recorded, quality of life assessment and
into post-2007 and pre-2007, to reflect before and after the pub
Demographic Anatomical Methods
Age
Sex
Race
Patient population
Comorbidity
Funtional status
Pre-treatment QOL
BMI
Height
Weight
Parity
Occupation
Smoking history
Civil status
Pre-treatment
imaging
Inclusion and
exclusion
criteria
CEAP
Clinical
examination
Indication
Pre-treatm
Method of
Intra-proce
Device or c
description
Energy sou
Total energ
dose of scl
Adjunctive
Anaesthesi
Length and
vein treate
Number of
phlebectom
Operation
APG, air plethysmography; AVP, ambulatory venous pressure; BMI, bod
QOL, quality of life; RT, refill time.Discussion
This study demonstrated that the published randomised trials
evaluating endovenous treatments vary hugely in reporting
and outcome measures assessed. Meaningful comparison
across randomised studies ismadedifficult by the variations in
study design and lack of adherence to published reporting
standards.7 Few studies provided relevant demographic data
of their subjects. Factors such as BMI10 and occupation11 are
known risk factors for varicose veins and associated symptoms
and also for subsequent complications from treatment, such
as wound infection.12 This highlights the necessity for accu-
rate recording of population characteristics. Moreover,
outcomes may vary hugely depending on CEAP grade. Only
nine studies provided detailed CEAP information, and only 2
studies limited their patient selection to a single CEAP class. A
separate analysis for each varicose vein clinical class and
access to the raw data may improve our understanding of
clinical outcomes in patients with different CEAP grades.
Kundu et al7 recommend that clinical and duplex follow-up
should be at uniform intervals, typically within the first 3 days
post-procedure, then at 1 month, 1 year after treatment, and
annually thereafter (1e3 years for mid-term follow-up, or
greater than 3 years for long term follow-up). The wide vari-
ation in time points seen within the trials makes direct
comparison of outcomes difficult to interpret. The use of QOL
questionnaires is another areawhere a significantdeficiencies
were seen. Anatomical measures of treatment efficacy in
isolation, in this context, are not a suitable measure of
treatment efficacy. The fact that sevendifferent types ofQOL
questionnaires were in use highlights the variety of availabletervention, with summary of treatment modalities compared,
time points for follow-up. These studies have been separated
lication of the American Venous Forum reporting standards.7
Outcome measures
ent preparation
vein access
dural Imaging
hemical agent
rce and duration
y deposited or
erosant
techniques
a type
diameter of
d
incisions or
ies
time
Primary outcome
Complications
- Immediate
- 30 day
- Follow-up imaging at regular
intervals
- Follow-up of clinical status
QOL measures
Cost or cost effectiveness
Requirement for further treatment
Uniform duration of follow-up
Recurrence
Questionnaires
CEAP
Analgesia requirements
Cosmesis
Time to resume work or
normal activity
AVP/RT
APG
y mass index; CEAP, clinical etiologic anatomic pathophysiologic;
532 B. Thakur et al.outcome measures within this particular category. The vari-
ation in reporting of complications represents the broad range
experienced by different clinicians. Reporting of even
common complications was inconsistent, with only eight
studies specifically assessing haematoma formation post-
procedure, and six studies mentioning incidence of DVT.
The heterogeneity seen within these trials can be
explained largely by the fact that our understanding of the
management of varicose veins has becomeprogressivelymore
sophisticated since the 1960s initiated by early randomised
trials in this field.40 The advent of new technologies for the
assessment and treatment of varicose veins, and methods for
recording treatment efficacy has resulted in a change in
methodology in randomised trials.Attemptswerefirstmade in
19944 to produce guidelines, although adherence to these and
other subsequent guidelines has been slow.
The implications of this study extend beyond trials per-
taining to varicose vein treatment. Reporting of population
and outcome data in randomised trials of new interventions
should be standardised in order to allow reliable compar-
ison between studies. Although we have only assessed trials
concerning endovenous treatment of varicose veins, similar
studies could be carried out for the treatment of venous
ulceration, or in fact for any modality for which a clearly
defined standard exists.
A limitation of this study is the fact that the most recent
reporting standards in endovenous ablation were published
in 2007,7 whereas most published studies included in this
review were published before 2007. If studies pre and post
2007 are considered separately, significant differences can
be seen. The recording of demographics is improved. All nine
of the post 2007 studies recorded patient’s age, and 8 of the
9 gave details of the gender. 3 studies post 2007 still did not
however use a validated QOL questionnaire, which highlights
that despite improvements in reporting standards in certain
aspects, there is still considerable lack of adherence to AVF
guidelines in crucial areas. It would therefore be important
to see if randomised trials in the future are more adherent to
the recommended standards. In conclusion, in trials evalu-
ating endovenous interventions for superficial venous reflux,
significant variations exist in the reporting of baseline
characteristics, outcome measures, length of follow-up. This
highlights the need for agreed reporting standards and
greater adherence to these standards, as this would allow
greater objectivity in the assessment of new technologies for
the treatment of varicose veins.
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